Suggested remit: To appraise the clinical and cost effectiveness of amivantamab with lazertinib within its marketing authorisation as a treatment for untreated EGFR mutation-positive advanced non-small-cell lung cancer (NSCLC).
- Status:
- In progress
- Technology type:
- Medicine
- Decision:
- Selected
- Reason for decision:
- Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
- Process:
- STA Standard
- ID number:
- 6256
Provisional Schedule
- Committee meeting: 2:
- 13 August 2025
- Expected publication:
- 23 October 2025
Project Team
- Project lead
- Jeremy Powell
Email enquiries
If you have any queries please email [email protected]
- External Assessment Group:
- School of Health and Related Research (ScHARR), University of Sheffield
Stakeholders
- Companies sponsors
- Johnson and Johnson (amivantamab, lazertinib)
- Others
- Department of Health and Social Care
- NHS England
- Patient carer groups
- EGFR Positive UK
- Roy Castle Lung Cancer Foundation
- Professional groups
- Association of Cancer Physicians
- Association of Respiratory Nurse Specialists
- British Thoracic Oncology Group
- Cancer Research UK
- Royal College of Physicians
- Royal College of Radiologists
- Comparator companies
- Amarox (erlotinib) - not participating
- AstraZeneca (gefitinib, osimertinib)
- Boehringer Ingelheim (afatinib) - not participating
- Cipla EU (gefitinib) - not participating
- Genus Pharmaceuticals (gefitinib) - not participating
- Glenmark Pharmaceutical (erlotinib) - not participating
- Mylan (erlotinib) - not participating
- Pfizer (dacomitinib) - not participating
- Roche (erlotinib) - not participating
- Sandoz (erlotinib, gefitinib) - not participating
- Zentiva (erlotinib) - not participating
- General commentators
- All Wales Therapeutics and Toxicology Centre
- British National Formulary
- Department of Health – Northern Ireland
- Healthcare Improvement Scotland
- Medicines and Healthcare products Regulatory Agency
- NHS Wales Joint Commissioning Committee
- Scottish Medicines Consortium
- Welsh Government
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 04 July 2025 - 25 July 2025 | Draft guidance |
| 12 June 2025 | Committee meeting |
| 30 October 2024 | Invitation to participate |
| 23 May 2024 - 21 June 2024 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6256 |
| 23 May 2024 | In progress. Scoping commenced. |
| 25 April 2024 | Please note that following on from a request received from the company, the timelines for this appraisal have been revised and the appraisal is now anticipated to begin in late October 2024. These timings are based on a request from the company to reschedule the initial date set by NICE, in order to facilitate a suitably comprehensive and robust submission. |
| 07 February 2023 | Awaiting development. Status change linked to Topic Selection Decision being set to Selected |
For further information on our processes and methods, please see our CHTE processes and methods manual